HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Clinical trials for HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) explained in plain language.
Never miss a new study
Get alerted when new HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) trials appear
Sign up with your email to follow new studies for HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug may keep leukemia away after transplant
Disease control Recruiting nowThis study tests whether a drug called ivosidenib can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. About 75 adults with a specific IDH1 gene mutation will receive either ivosidenib or a placebo daily for up to two years. The goal is to …
Matched conditions: HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New inhaled drug aims to stop lung infections in vulnerable cancer patients
Disease control Recruiting nowThis study tests an experimental inhaled drug called PUL-042 in 100 people with blood cancers (like leukemia or lymphoma) or who have had a stem cell transplant and caught a lung virus (PIV, hMPV, or RSV). The goal is to see if PUL-042 can prevent or reduce serious lung complicat…
Matched conditions: HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Phase: PHASE2 • Sponsor: Pulmotect, Inc. • Aim: Disease control
Last updated Jun 09, 2026 12:10 UTC